CN103012621B - A kind of High-purity heparin benzyl ester salt and its preparation method and application - Google Patents
A kind of High-purity heparin benzyl ester salt and its preparation method and application Download PDFInfo
- Publication number
- CN103012621B CN103012621B CN201110288821.6A CN201110288821A CN103012621B CN 103012621 B CN103012621 B CN 103012621B CN 201110288821 A CN201110288821 A CN 201110288821A CN 103012621 B CN103012621 B CN 103012621B
- Authority
- CN
- China
- Prior art keywords
- salt
- benzyl ester
- heparin
- alkali
- alkali metal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of High-purity heparin benzyl ester salt and its preparation method and application.Specifically, the heparin benzyl ester salt of the present invention is by after the aqueous reactant solution of the heparin benzyl ester salt containing quaternary ammonium salt and alkali metal or alkali salt, the insoluble solvent added for heparin benzyl ester metal salt or alkali salt, precipitation separation is made, and with following characteristic：Heparin benzyl ester purity salt is high, and particularly quaternary ammonium salt residual is low, and preparation method is simple, it is easy to industrialized production, available for the LMWHs for preparing high-purity, high income.
Description
Technical field
The present invention relates to by a kind of High-purity heparin benzyl ester salt, and preparation method thereof with LMWHs is prepared should
With.
Background technology
Heparin is the sulfated polysaccharide mixture in animal (pig or ox) source, because they have good antithrombus formation
Matter, thus be widely applied, for example prepare anti-thrombosis drug, the medicine for treating angiocardiopathy and treatment brain blood
Medicine of pipe disease etc..
However, Natural heparin has many defects, these defects limit the application of heparin.One major defect is heparin medication
Hematostaxis can be excessively caused, therefore the clotting time should be determined before per injection.In addition, being used for a long time, heparin can also cause allergy
Reaction, decrease of platelet, osteoporosis and spontaneous fracture.
Liquaemin hematostaxis is dangerous very big, and the clotting time must be monitored in Clinical practice, and this is equal to doctor and patient
Bring very big inconvenience.Meanwhile, the adverse reaction such as decrease of platelet and osteoporosis also allows doctor to have certain scruples in use.Low point
The clotting time need not be monitored during sub- heparin use, and greatly reduces heparin the above-mentioned bad anti-of generation is used for a long time
Should.
At present, preparing the main method of LMWHs has nitrite degradation method, hydrogen peroxide degradation method, heparinase drop
Alkaline degradation method of solution and heparin benzyl ester etc..Wherein, into salt, then the alkaline degradation method of heparin benzyl ester is by heparin and quaternary ammonium salt
Esterification generation heparin benzyl ester quaternary ammonium salt is occurred into dichloromethane for heparin quaternary ammonium salt and benzyl chloride, added into this solution
Sodium acetate methanol solution, filtering obtains heparin benzyl ester sodium salt, according to the height of esterification yield, corresponding degradation condition is selected, by this
Sodium salt is degraded in alkaline solution, obtains LMWHs.As can be seen here, how Accurate Determining esterification yield is entirely being prepared
It is very crucial in method.Further, since LMWHs is mixture, process control impurity becomes extremely important.Therefore, it is high-purity
The heparin benzyl ester alkali metal or alkali salt of degree are the premises for obtaining high-quality LMWHs.
However, above-mentioned preparation method has as a drawback that：(1) heparin benzyl ester sodium salt purity is low：When sodium acetate methanol solution
When generating heparin benzyl ester sodium salt with heparin benzyl ester quaternary ammonium reactant salt, because heparin is macromolecular long-chain, heparin benzyl ester sodium salt is in first
Solubility is very low in alcohol, with the addition of sodium acetate methanol solution, has little time the heparin benzyl ester sodium salt containing quaternary ammonium salt of reaction
It is precipitated simultaneously, so causes reaction incomplete.Even if it is demonstrated experimentally that carry out for a long time stirring or repeatedly with sodium acetate first
Alcoholic solution repeats to react, but is suspension after all, still has substantial portion of quaternary ammonium salt to be unable to total overall reaction, so as to remain in liver
On plain benzyl ester sodium salt chain.(2) esterification yield of heparin benzyl ester sodium salt is difficult to accurate measure：Because reaction is non-solution state, reaction
Thing and product are precipitation, and the degree per secondary response is difficult to reappear, and quaternary ammonium salt, benzyl chloride and sodium acetate residual have every time
Difference, this brings uncertainty to the measure of esterification yield, so as to influence the selection of follow-up degradation condition, and then influences product
Quality, or even can influence production success rate.(3) safety risks of final products：The quaternary ammonium salt generated in course of reaction
It is difficult to be washed off by methanol with excessive benzyl chloride, sodium acetate, can remains in heparin benzyl ester sodium salt.Also can in subsequent degradation
New impurity is produced, the security to product brings hidden danger.
Also have in document and mention, after generation heparin benzyl ester quaternary ammonium salt, first action solvent tetrahydrofuran is directly distilled off,
Then methanol suspension precipitation is added, filtering obtains heparin benzyl ester quaternary ammonium salt, is then added into the aqueous solution of sodium acetate, generates liver
Plain benzyl ester sodium salt.This preparation method needs that action solvent is first distilled off, and it is demonstrated experimentally that heparin benzyl ester quaternary ammonium salt is soluble in
Methanol, thus boil off after action solvent add methanol can not be precipitated, while considerably increase industrialization difficulty and into
This.
Therefore, this area is in the urgent need to the heparin benzyl ester salt of exploitation high-purity, and simple possible, the system for being adapted to industrialization
Preparation Method and its application in LMWHs preparation.
The content of the invention
It is an object of the invention to provide a kind of heparin benzyl ester salt of high-purity, and its simple possible, suitable industrialization
Preparation method and its LMWHs preparation in application.
In the first aspect of the present invention, there is provided the preparation of a kind of High-purity heparin benzyl ester alkali metal salt or alkali salt
Method, including step：
(a) by the heparin benzyl ester salt containing quaternary ammonium salt, mixed with the aqueous solution of alkali metal or alkali salt, from
And react generation heparin benzyl ester alkali metal salt or alkali salt；With
(b) in step (a) institute formation reactant mixture, add for heparin benzyl ester alkali metal salt or alkali salt
The insoluble solvent of speech, so as to precipitate and isolate the heparin benzyl ester alkali metal salt or alkali salt.
In another preference, the heparin benzyl ester salt containing quaternary ammonium salt is that heparin quaternary ammonium salt exists with benzylic halides
The reaction product of esterification generation occurs in organic solvent.
Heparin derives from ox, the heparin of pig, i.e. pork liver element or beef liver element and its derivative.
In another preference, the benzylic halides are halogenation benzyl, preferably benzyl chloride or cylite, more preferably chlorination
Benzyl.
In another preference, the organic solvent is dichloromethane.
In another preference, the alkali metal salt is sodium chloride, sodium acetate, potassium chloride or sodium sulphate；The alkaline earth gold
It is calcium chloride or magnesium chloride to belong to salt.
Preferably sodium acetate, is more preferably sodium chloride.
In another preference, the aqueous solution concentration of the alkali metal salt or alkali salt is 0.1w/v%~95w/
V%.
In another preference, the aqueous solution concentration of the alkali metal salt or alkali salt is 3w/v%~50w/
V%.
In another preference, the aqueous solution concentration of the alkali metal salt or alkali salt is 5w/v%~25w/
V%.
In another preference, the alkali metal salt or alkali salt and the heparin benzyl ester salt containing quaternary ammonium salt
Weight ratio is 0.1~10: 1.
In another preference, the alkali metal salt or alkali salt and the heparin benzyl ester salt containing quaternary ammonium salt
Weight ratio is 0.2~5: 1.
In another preference, the alkali metal salt or alkali salt and the heparin benzyl ester salt containing quaternary ammonium salt
Weight ratio is 0.5~1: 1.
In another preference, the solvent of described aqueous solution is water or containing methanol, ethanol, acetone or its combination
The aqueous solution.
In another preference, described insoluble solvent is selected from the group：Alcohol, ketone or its combination.
More preferably, described alcohol is methanol, ethanol or its combination；The ketone is acetone.
There is provided the heparin benzyl alkali metal salt or alkali salt of a kind of high-purity, impurity season for the second aspect of the present invention
The content ＜ 5wt% of ammonium salt.
In another preference, the content ＜ 1wt% of the impurity quaternary ammonium salt, preferably, the impurity quaternary ammonium salt contains
Measure ＜ 0.5wt%, the content ＜ 0.1wt% of more preferably described impurity quaternary ammonium salt.
In another preference, described heparin benzyl ester metal salt includes heparin benzyl ester sodium salt, sylvite, calcium salt or magnesium salts shape
Formula.
In another preference, described heparin benzyl ester metal salt is heparin benzyl ester sodium salt.
In another preference, described heparin benzyl ester alkali metal salt or alkali salt are to use first aspect methods described
Prepare.
The third aspect of the present invention comprises the following steps there is provided a kind of method for the polysaccharide mixture for preparing heparin derivative：
(a) by the heparin benzyl ester salt containing quaternary ammonium salt, mixed with the aqueous solution of alkali metal or alkali salt, from
And react generation heparin benzyl ester alkali metal salt or alkali salt；With
(b) in step (a) institute formation reactant mixture, add for heparin benzyl ester alkali metal salt or alkali salt
The insoluble solvent of speech, so as to precipitate and isolate the heparin benzyl ester alkali metal salt or alkali salt；
(c) heparin benzyl ester alkali metal salt or alkali salt are subjected to the polysaccharide mixing that alkaline degradation obtains the heparin derivative
Thing.
In another preference, the heparin benzyl ester salt containing quaternary ammonium salt is that heparin quaternary ammonium salt exists with benzylic halides
The reaction product of esterification generation occurs in organic solvent.
Heparin derives from ox, the heparin of pig, i.e. pork liver element or beef liver element and its derivative.
In another preference, the benzylic halides are halogenation benzyl, preferably benzyl chloride or cylite, more preferably chlorination
Benzyl.
In another preference, the organic solvent is dichloromethane.
In another preference, the alkali metal salt is sodium chloride, sodium acetate, potassium chloride or sodium sulphate；The alkaline earth gold
It is calcium chloride or magnesium chloride to belong to salt.
Preferably sodium acetate, is more preferably sodium chloride.
In another preference, the aqueous solution concentration of the alkali metal salt or alkali salt is 0.1w/v%~95w/
V%.
In another preference, the aqueous solution concentration of the alkali metal salt or alkali salt is 3w/v%~50w/
V%.
In another preference, the aqueous solution concentration of the alkali metal salt or alkali salt is 5w/v%~25w/
V%.
In another preference, the alkali metal salt or alkali salt and the heparin benzyl ester salt containing quaternary ammonium salt
Weight ratio is 0.1~10: 1.
In another preference, the alkali metal salt or alkali salt and the heparin benzyl ester salt containing quaternary ammonium salt
Weight ratio is 0.2~5: 1.
In another preference, the alkali metal salt or alkali salt and the heparin benzyl ester salt containing quaternary ammonium salt
Weight ratio is 0.5~1: 1.
In another preference, the solvent of described aqueous solution is water or containing methanol, ethanol, acetone or its combination
The aqueous solution.
In another preference, described insoluble solvent is selected from the group：Alcohol, ketone or its combination.
More preferably, described alcohol is methanol, ethanol or its combination；The ketone is acetone.
The fourth aspect of the present invention is there is provided a kind of polysaccharide mixture of heparin derivative, with following characteristics：
It is prepared by the method described in the third aspect；
Weight average molecular weight is no more than 8000 dalton；
Anticoagulin Xa and anticoagulin IIa activity ratio is to be not less than 1.5；
In its non-reducing end, contain 4- pyrans uronic acid structures.
In another preference, the polysaccharide mixture of heparin derivative, with following characteristics：
It is prepared by the method described in the third aspect；
Weight average molecular weight is 3800-5000 dalton；
Molecular weight is the 12~20% of gross weight less than the content of 2000 dalton；
Molecular weight is between the 68%-82% that the content of 2000-8000 dalton is gross weight；
Anticoagulin Xa and anticoagulin IIa activity ratio is 3.3-5.3；
In its non-reducing end, containing 4- pyrans uronic acid structures, reduction end contains 15~25% 1,6- dehydration rings
Structure.
In another preference, the polysaccharide mixture of the heparin derivative prepared by the method described in the third aspect has
Following characteristics：
Weight average molecular weight is 1500-5000 dalton；
Anticoagulin Xa and anticoagulin IIa activity ratio is to be not less than 10；
In its non-reducing end, contain 4- pyrans uronic acid structures.
In another preference, the polysaccharide mixture is in alkali metal salt or alkaline earth metal salt, wherein, preferred sodium
Salt, sylvite, calcium salt and magnesium salts.
The fifth aspect of the present invention contains the 4th as active component there is provided a kind of pharmaceutical composition, the composition
The polysaccharide mixture and pharmaceutically acceptable carrier of heparin derivative described in aspect.
The sixth aspect of the present invention there is provided the purposes of High-purity heparin benzyl ester alkali metal salt or alkali salt, by with
In the polysaccharide mixture for the heparin derivative for preparing high-purity, including following preparation process：
(a) by the heparin benzyl ester salt containing quaternary ammonium salt, mixed with the aqueous solution of alkali metal or alkali salt, from
And react generation heparin benzyl ester alkali metal salt or alkali salt；With
(b) in step (a) institute formation reactant mixture, add for heparin benzyl ester alkali metal salt or alkali salt
The insoluble solvent of speech, so as to precipitate and isolate the heparin benzyl ester alkali metal salt or alkali salt；
(c) heparin benzyl ester alkali metal salt or alkali salt are subjected to the polysaccharide mixing that alkaline degradation obtains the heparin derivative
Thing
The High-purity heparin benzyl ester alkali metal salt or alkaline-earth metal purity salt that the present invention is provided are high, and particularly quaternary ammonium salt is remained
Low, preparation method is simple, it is easy to industrialized production, available for the LMWHs for preparing high-purity, high income.
Embodiment
The present inventor is by in-depth study extensively, by the preparation method for improving heparin benzyl ester salt, it has unexpectedly been found that,
The aqueous solution of heparin benzyl ester salt and alkali metal salt or alkali salt containing quaternary ammonium salt is reacted, can efficiently, letter
Just, rapidly prepare high-purity and quaternary ammonium salt, benzyl chloride and sodium acetate remain low heparin benzyl ester alkali metal salt or alkaline-earth metal
Salt.The present invention is completed on this basis.
The heparin benzyl ester salt of the present invention has following major advantage：(1) purity is high：Quaternary ammonium salt residual quantity is usually less than
3wt%, benzyl chloride residual is usually less than 0.1wt%, and sodium acetate residual quantity is usually less than 0.1wt%.(2) esterification yield is easy to determine
And control, be conducive to the application in prepared by LMWHs.(3) it is soluble in water, be conducive to it in LMWHs preparation
Application, i.e., be easier to select suitable degradation condition when preparing LMWHs.(4) when preparing LMWHs, no season
The impurity of the introducings such as ammonium salt, benzyl chloride and sodium acetate, pigment content is low and is easy to remove, and quality is good, high income.
As used herein, term " heparin " refers to the polysaccharide of the dalton of molecular weight ranges 2000~30000.
In the present invention, aqueous solvent or aqueous solvent can be used, forms solution and is commonly referred to as aqueous solution.In other words, alkali
The aqueous solution of metal salt or alkali salt, it is alkali metal or alkaline-earth metal to refer to solute, be dissolved in solvent for (a) water or
(b) mixed solvent that water is formed with organic solvent (such as methanol, ethanol) is (for example, mixing of the alcohol content less than 90% (V/V) is molten
Agent can be considered the solvent of aqueous solution) solution that is formed.
The preferred aqueous mixed solvent of one class is that water and organic solvent (such as methanol, ethanol) volume ratio are 10-100:
0.01-90 (preferably 20-100: 0.1-80, more preferably 50-100: 1-50) mixed solvent.
Heparin benzyl ester alkali metal salt or alkali salt
The heparin benzyl ester alkali metal salt or alkali salt of the present invention can be adopted to be prepared with the following method：Contain quaternary ammonium salt
Heparin benzyl ester salt and alkali metal or the aqueous reactant solution of alkali salt, obtain heparin benzyl ester alkali metal salt or alkaline-earth metal
Salt, the insoluble solvent added into this reaction system for heparin benzyl ester metal salt or alkali salt, so as to precipitate
Isolate heparin benzyl ester alkali metal salt of the present invention or alkali salt.
In the preference of the present invention, described preparation method includes step：
(a) the heparin benzyl ester salt containing quaternary ammonium salt and alkali metal or the aqueous reactant solution of alkali salt, obtain heparin
Benzyl ester alkali metal salt or alkali salt suspension；With
(b) toward adding the insoluble solvent for heparin benzyl ester alkali metal salt or alkali salt in above-mentioned system,
Heparin benzyl ester alkali metal salt of the present invention or alkali salt are isolated so as to precipitate.
In the present invention, as alkali metal salt or alkali salt, preferably sodium, potassium, calcium and magnesium salts.
Described insoluble solvent is selected from the group：Alcohol, ketone or its combination.
More preferably, described alcohol is methanol, ethanol or its combination；The ketone is acetone.
The heparin benzyl ester salt of the present invention, they are compared with the heparin benzyl ester salt prepared by existing document, with higher
Purity and it is easier to quality control.In other words, heparin benzyl ester purity salt is very high, and the impurity such as quaternary ammonium salt, benzyl chloride and sodium acetate
Content is very low.For example, quaternary ammonium salt impurities content≤3wt%, preferably≤1wt% in heparin benzyl ester salt of the present invention, more preferably≤
0.5wt%.
These heparin benzyl ester salt can be in alkali metal salt or alkaline earth metal salt, wherein, particular certain cancers, sylvite, calcium salt
And magnesium salts.
The polysaccharide mixture of heparin derivative
According to the esterification yield of the heparin benzyl ester salt of high-purity, it can be degraded using corresponding conditionses, obtain high-purity
Heparin derivative polysaccharide mixture, such as Enoxaparin Sodium LMWHs.In the polysaccharide mixture of these heparin derivatives,
There is undersaturated 4,5- glucuronic acids 2-O- sulfuric ester construction units in its one end.
Pharmaceutical composition and application process
The polysaccharide mixture of the heparin derivative of the present invention may be used as antithrombotic agent, prevent venous thrombo-embolic disease
Disease (the intravenous thrombosis of prevention), the particularly thrombosis relevant with orthopaedics or general surgical operation.Treat established depth quiet
Arteries and veins embolism, with or without pulmonary embolism.Unstable angina and non-Q ripples heart infarction are treated, in haemodialysis extracorporal circulatory system, preventing
Tampon is formed.
In addition, the polysaccharide mixture of the heparin derivative of the present invention can be additionally used in treatment or adjuvant therapy of cardiovascular disease and brain
Vascular diseases.
Therefore, the present invention also provides a kind of pharmaceutical composition, and it contains the heparin derivative of the invention as active component
Polysaccharide mixture and pharmaceutically acceptable carrier.Generally, in pharmaceutical composition, the polysaccharide of heparin derivative of the invention is mixed
The content of compound is 0.01-50wt%, is more preferably 0.1-30wt%.A kind of preferred medicine composition dosage form is injection
(including solution and freeze-dried).
The pharmaceutical composition of the present invention can be prepared and applied with conventional method.A kind of preferred application process is subcutaneous or quiet
It is administered in arteries and veins.
Main advantages of the present invention are：
(1) heparin benzyl ester purity salt is high, and quaternary ammonium salt, benzyl chloride and acetic acid salt residual quantity are low, and usual weight content is less than
5%.
(2) quality control of heparin benzyl ester salt is simple, and particularly key index esterification yield can be with Accurate Determining and control.
(3) polysaccharide mixture of heparin derivative prepared by application High-purity heparin benzyl ester salt, product purity is high, security
It is good, it will not introduce due to the impurity that intermediate is impure and produces, such as quaternary ammonium salt content ＜ 0.1wt%.
With reference to specific embodiment, the present invention is expanded on further.It should be understood that these embodiments are merely to illustrate the present invention
Rather than limitation the scope of the present invention.The experimental method of unreceipted actual conditions in the following example, generally according to conventional strip
Part is (such as《European Pharmacopoeia》Described in condition), or according to the condition proposed by manufacturer.
General assay method
(1) degree of esterification of heparin ester or heparin ester salt can be determined with conventional HPLC, i.e., by determining at 0 DEG C
Phenmethylol amount produced by saponification by ester determines degree of esterification.
(2) molecular weight and molecualr weight distribution and anti-Xa and anti-IIa potency use low molecule conventional in European Pharmacopoeia
The method of heparin quality standard is carried out.
Embodiment 1
The preparation of heparin benzyloxy b ammonium salt
Into benzethonium chloride (250g) aqueous solution (1250ml), the water containing commercially available liquaemin (100g) is added
(1000ml) solution (note：The heparin in pig source).Stirring is lower to place 30 minutes, forms heparin benzyloxy b ammonium salt precipitation.Then, will
Reactant mixture is filtered at room temperature, obtains filter cake, is dried in vacuo after being washed with water, and obtains heparin benzyloxy b ammonium salt (300 grams).
Embodiment 2
The preparation of heparin benzyl ester sodium salt
Benzyl chloride (100ml) is added in heparin benzyloxy b ammonium salt (100g) dichloromethane (500ml) solution.By solution
35 DEG C are heated to, is maintained 25 hours.Then add 10% sodium acetate methanol solution (600ml).Stirring, separates out precipitation, filters,
A small amount of methanol top is washed, and is dried, is obtained flaxen heparin benzyl ester sodium salt crude product (38 grams).
Dried heparin benzyl ester sodium salt crude product is dissolved in 800ml water, 100g sodium chloride is added, stirring is lower to be added
2400ml methanol, filters the precipitation separated out, and a small amount of methanol top is washed, and is dried to obtain the white heparin benzyl ester sodium salt (35g) of high-purity.
Determined through HPLC methods, in the heparin benzyl ester sodium salt, the residual quantity ＜ 0.4wt% of quaternary ammonium salt, the residual of sodium acetate
＜ 0.1wt%, the residual quantity ＜ 0.1wt% of benzyl chloride are measured, esterification yield is 12.3% (w/w).
Embodiment 3
The preparation of heparin benzyl ester sodium salt
Benzyl chloride (100ml) is added in heparin benzyloxy b ammonium salt (100g) dichloromethane (500ml) solution.By solution
35 DEG C are heated to, is maintained 20 hours.Then the sodium acetate methanol solution (700ml) of addition 10%, stirring, separate out precipitation, centrifuge,
Dry, obtain flaxen heparin benzyl ester sodium salt crude product (38 grams).
Dried heparin benzyl ester sodium salt crude product is dissolved in 800ml water, 80g sodium chloride is added, stirring is lower to be added
2400ml methanol, filters the precipitation separated out, the white heparin benzyl ester sodium salt (34g) of dry high-purity.
Through HPLC methods determine, in the heparin benzyl ester sodium salt, the residual quantity ＜ 0.5wt% of quaternary ammonium salt, sodium acetate it is residual
Allowance ＜ 0.1wt%, the residual quantity ＜ 0.1wt% of benzyl chloride, esterification yield are 11.9% (w/w).
Embodiment 4
The preparation of heparin benzyl ester sodium salt
Benzyl chloride (100ml) is added in heparin benzyloxy b ammonium salt (100g) dichloromethane (500ml) solution.By solution
35 DEG C are heated to, is maintained 25 hours.Then the acetic acid sodium ethoxide solution (800ml) of addition 10%, separates out precipitation, filters, and dries,
Thus flaxen heparin benzyl ester sodium salt crude product (37 grams) is obtained.
Dried heparin benzyl ester sodium salt crude product is dissolved in 800ml water, 80g sodium chloride is added, stirring is lower to be added
2400ml ethanol, filters the precipitation separated out, the white heparin benzyl ester sodium salt (35g) of dry high-purity.
Through HPLC methods determine, in the heparin benzyl ester sodium salt, the residual quantity ＜ 0.5wt% of quaternary ammonium salt, sodium acetate it is residual
Allowance ＜ 0.1wt%, the residual quantity ＜ 0.1wt% of benzyl chloride, esterification yield are 13.1% (w/w).
Embodiment 5
The preparation of heparin benzyl ester sodium salt
Benzyl chloride (100ml) is added in heparin benzyloxy b ammonium salt (100g) dichloromethane (500ml) solution.By solution
40 DEG C are heated to, is maintained 20 hours.Then after the sodium acetate methanol solution (1000ml) for adding 10%, precipitation is separated out, is filtered, it is few
After amount methanol top is washed, heparin benzyl ester sodium salt crude product filter cake is dissolved in 800ml water, 80g sodium chloride is added, stirring is lower to be added
2400ml ethanol, filters the precipitation separated out, the white heparin benzyl ester sodium salt (33g) of dry high-purity.
Through HPLC methods determine, in the heparin benzyl ester sodium salt, the residual quantity ＜ 0.4wt% of quaternary ammonium salt, sodium acetate it is residual
Allowance ＜ 0.1wt%, the residual quantity ＜ 0.1wt% of benzyl chloride, esterification yield are 10.8% (w/w).
Embodiment 2-5 results show that preparation method of the present invention is simple, favorable reproducibility, and heparin benzyl ester sodium salt purity is high, is
White, quaternary ammonium salt, sodium acetate and benzyl chloride residual are low.
Embodiment 6
The application of heparin benzyl ester salt
The heparin benzyl ester sodium salt (10g) that embodiment 2 is obtained is dissolved in water (250ml), is heated to 62 DEG C.Into this solution
Sodium hydroxide (1g) is added, is reacted 1.5 hours, so that heparin benzyl ester sodium salt is degraded.Then reactant mixture is cooled to about
20 DEG C, add watery hydrochloric acid and neutralized.Sodium chloride is added so that the sodium chloride concentration in reactant mixture is 10% (w/v).
Methanol (750ml) is added into reactant mixture, precipitation is separated out, filtering obtains filter cake, after methanol washing, filter cake is dissolved in
In 100ml water.PH to 8.4 ± 0.1 is adjusted with 1M NaOH.Sodium borohydride (based on 10g/kg heparin benzyl ester sodium salts) is added to
In the solution, 1 hour is stood, then adjusts pH to 4.0-4.4 to eliminate excessive boron hydride with 3M hydrochloric acid.Stand 30
Minute, and adjust pH to 7.0 with 2M NaOH.Sodium chloride is added, it is 10w/v% to make salinity, then adds 3 times of liquor capacity
The methanol of volume, separates out precipitation, filtering obtains filter cake, after being washed with methanol, vacuum drying, so as to obtain the low molecule of high-purity
Heparin (white, 7.9g).In terms of liquaemin, yield is 83.0%.
After measured, the property of the polysaccharide mixture of described heparin derivative is as follows：
| Measured value | Standard | |
| Weight average molecular weight (dalton) | 4518 | 3800~5000 |
| Molecular weight is less than the constituent content of 2000 dalton | 16% | 12~20% |
| Constituent content of the molecular weight between 2000~8000 dalton | 78% | 68-82% |
| Anticoagulin xa activity (IU/ milligrams) | 101.7 | 90-125IU/mg |
| Anticoagulin IIa activity (IU/ milligrams) | 21.6 | 20-35IU/mg |
| Anticoagulin xa activity/anticoagulin IIa activity ratio | 4.7 | 3.3~5.3 |
| 1,6- dehydration ring content | 21.3% | 15~25% |
Detected through HPLC, quaternary ammonium salt ＜ 0.01wt% in product, purity is high, security is good.
Therefore, the polysaccharide mixture of the heparin derivative prepared using preparation method of the present invention, complies fully with listing according to promise liver
The quality requirement of plain sodium.Meanwhile, the preparation method yield is high, without cumbersome and prolonged filtration treatment step and a large amount of methanol
Filter cake is rinsed, cost and energy consumption is advantageously reduced, greatly strengthen the competitiveness of product.
Embodiment 7
The application of heparin benzyl ester salt
The heparin benzyl ester sodium salt (10g) that embodiment 3 is obtained is dissolved in water (250ml), is heated to 62 DEG C.Into this solution
Sodium hydroxide (1g) is added, is reacted 1.5 hours, so that heparin benzyl ester sodium salt is degraded.Then reactant mixture is cooled to about
20 DEG C, add hydrochloric acid and neutralized.Sodium chloride is added so that the sodium chloride concentration in reactant mixture is 10% (w/v).To
Methanol (750ml) is added in reactant mixture, precipitation is separated out, filtering obtains filter cake, after methanol washing, filter cake is dissolved in into 100ml
In water.PH to 8.4 ± 0.1 is adjusted with 1M NaOH.Sodium borohydride (based on 10g/kg heparin benzyl ester sodium salts) is added to the solution
In, 1 hour is stood, then adjusts pH to 4.0-4.4 to eliminate excessive boron hydride with 3M hydrochloric acid.30 minutes are stood,
And adjust pH to 7.0 with 2M NaOH.Sodium chloride is added, it is 12w/v% to make salinity, then adds 3 times of volumes of liquor capacity
Methanol, separates out precipitation, filtering obtains filter cake, after being washed with methanol, vacuum drying, so as to obtain the LMWHs of high-purity
(white, 7.9g).Calculated by liquaemin, yield is 80.6%.
After measured, the property of the polysaccharide mixture of described heparin derivative is as follows：
| Measured value | Standard | |
| Weight average molecular weight (dalton) | 4523 | 3800~5000 |
| Molecular weight is less than the constituent content of 2000 dalton | 14% | 12~20% |
| Constituent content of the molecular weight between 2000~8000 dalton | 75% | 68~82% |
| Anticoagulin xa activity (IU/ milligrams) | 103.7 | 90~125 |
| Anticoagulin IIa activity (IU/ milligrams) | 24.1 | 20~35 |
| Anticoagulin xa activity/anticoagulin IIa activity ratio | 4.3 | 3.3~5.3 |
| 1,6- dehydration ring content | 20.8% | 15~25% |
Detected through HPLC, quaternary ammonium salt ＜ 0.01wt% in product, purity is high, security is good.
Embodiment 8
The application of heparin benzyl ester salt
The heparin benzyl ester sodium salt (10g) that embodiment 4 is obtained is dissolved in water (250ml), is heated to 60 DEG C.Into this solution
Sodium hydroxide (1g) is added, is reacted 1.5 hours, so that heparin benzyl ester sodium salt is degraded.Then reactant mixture is cooled to about
20 DEG C, add hydrochloric acid and neutralized.Sodium chloride is added so that the sodium chloride concentration in reactant mixture is 10% (w/v).To
Methanol (750ml) is added in reactant mixture, precipitation is separated out, filtering obtains filter cake, after methanol washing, filter cake is dissolved in into 100ml
In water.PH to 8.4 ± 0.1 is adjusted with 1M NaOH.Sodium borohydride (based on 10g/kg heparin benzyl ester sodium salts) is added to the solution
In, 1 hour is stood, then adjusts pH to 4.0-4.4 to eliminate excessive boron hydride with 3M hydrochloric acid.30 minutes are stood,
And adjust pH to 7.0 with 2M NaOH.Sodium chloride is added, it is 10w/v% to make salinity, then adds 3 times of volumes of liquor capacity
Ethanol, separates out precipitation, filtering obtains filter cake, after being washed with methanol, vacuum drying, so as to obtain the LMWHs of high-purity
(white, 8.1g).Calculated with liquaemin, yield is 85.1%.
After measured, the property of the polysaccharide mixture of described heparin derivative is as follows：
| Measured value | Standard | |
| Weight average molecular weight (dalton) | 4489 | 3800~5000 |
| Molecular weight is less than the constituent content of 2000 dalton | 18% | 12~20% |
| Constituent content of the molecular weight between 2000~8000 dalton | 75% | 68~82% |
| Anticoagulin xa activity (IU/ milligrams) | 98.3 | 90~125 |
| Anticoagulin IIa activity (IU/ milligrams) | 20.5 | 20~35 |
| Anticoagulin xa activity/anticoagulin IIa activity ratio | 4.8 | 3.3~5.3 |
| 1,6- dehydration ring content | 19.8% | 15~25% |
Detected through HPLC methods, quaternary ammonium salt ＜ 0.01wt% in this LMWHs, purity is high, security is good.
Embodiment 9
The application of heparin benzyl ester salt
The heparin benzyl ester sodium salt (10g) that embodiment 5 is obtained is dissolved in water (250ml), is heated to 64 DEG C.Into this solution
Sodium hydroxide (1.1g) is added, is reacted 1.5 hours, so that heparin benzyl ester sodium salt is degraded.Then reactant mixture is cooled to
About 20 DEG C, add hydrochloric acid and neutralized.Sodium chloride is added so that the sodium chloride concentration in reactant mixture is 10% (w/v).
Methanol (750ml) is added into reactant mixture, precipitation is separated out, filtering obtains filter cake, after methanol washing, filter cake is dissolved in
In 100ml water.5ml hydrogen peroxide is added into the solution, after reacting 1 hour, sodium chloride is added, it is 10w/v% to make salinity, plus
Enter the methanol of 3 times of volumes of solution, separate out precipitation, filtering obtains filter cake, after being washed with methanol, vacuum drying, so as to obtain high-purity
The LMWHs (white, 8.1) of degree.Calculated with liquaemin, yield is 80.2%.
After measured, the property of the polysaccharide mixture of described heparin derivative is as follows：
| Measured value | Standard | |
| Weight average molecular weight (dalton) | 4532 | 3800~5000 |
| Molecular weight is less than the constituent content of 2000 dalton | 18% | 12~20% |
| Constituent content of the molecular weight between 2000~8000 dalton | 77% | 68~82% |
| Anticoagulin xa activity (IU/ milligrams) | 113.5 | 90~125 |
| Anticoagulin IIa activity (IU/ milligrams) | 29.1 | 20~35 |
| Anticoagulin xa activity/anticoagulin IIa activity ratio | 3.9 | 3.3~5.3 |
| 1,6- dehydration ring content | 22.6% | 15~25% |
Detected through HPLC methods, quaternary ammonium salt ＜ 0.01wt% in this LMWHs, purity is high, security is good.
Embodiment 10
The application of heparin benzyl ester salt
The heparin benzyl ester sodium salt (10g) that embodiment 4 is obtained is dissolved in water (250ml), and solution achromaticity and clarification is heated to 65
℃.Sodium hydroxide (1.1g) is added into this solution, is reacted 1.5 hours, so that heparin benzyl ester sodium salt is degraded, reaction solution becomes
Faint yellow settled solution.The solution is cooled to about 20 DEG C, hydrochloric acid is added and is neutralized.Adding sodium chloride causes reaction to mix
Sodium chloride concentration in thing is 10% (w/v).Methanol (750ml) is added into reactant mixture, precipitation is separated out, is filtered
Cake, after methanol washing, filter cake is dissolved in 100ml water.5ml hydrogen peroxide is added into the solution, after reacting 1 hour, chlorine is added
Change sodium, it is 10w/v% to make salinity, adds the methanol of 3 times of volumes of liquor capacity, separate out precipitation, filtering obtains filter cake, uses methanol
After washing, vacuum drying, so as to obtain the LMWHs (white, 6.9g) of high-purity.Calculated by liquaemin, yield is
72.5%.
After measured, the property of the polysaccharide mixture of described heparin derivative is as follows：
| Measured value | |
| Weight average molecular weight (dalton) | 3593 |
| Molecular weight is less than the constituent content of 2000 dalton | 14% |
| Molecular weight is more than the constituent content of 5000 dalton | 3% |
| Anticoagulin xa activity (IU/ milligrams) | 102.7 |
| Anticoagulin IIa activity (IU/ milligrams) | 33.1 |
| Anticoagulin xa activity/anticoagulin IIa activity ratio | 3.1 |
Detected through HPLC, quaternary ammonium salt ＜ 0.01wt% in product, purity is high, security is good.
Embodiment 6-9 shows that the heparin benzyl ester salt obtained using the present invention is intermediate, the LMWHs of preparation, matter
Amount is controllable, and high income, impurity is few, and purity is high, and Product Safety is good, complies fully with the quality requirement of listing Enoxaparin Sodium.Together
When, the preparation method yield is high, rinses filter cake without cumbersome and prolonged filtration treatment step and a large amount of methanol, is conducive to drop
Low cost and energy consumption, greatly strengthen the competitiveness of product.
Show from embodiment 8 and 10, according to the difference of esterification yield, using different degradation conditions, specific molecular can be obtained
Amount distribution and the LMWHs of potency feature.
Comparative example 1
The preparation of heparin benzyl ester sodium salt
Benzyl chloride (100ml) is added in heparin benzyloxy b ammonium salt (100g) dichloromethane (500ml) solution.By solution
35 DEG C are heated to, is maintained 25 hours.Then add 10% sodium acetate methanol solution (600ml).Separate out precipitation, long-time mistake
Filter, filter cake is rinsed with 5L methanol, is dried, is thus obtained off-white color heparin benzyl ester sodium salt (36 grams).
Determined through HPLC methods, in the heparin benzyl ester sodium salt, the content of quaternary ammonium salt is 17wt%, and the content of sodium acetate is
15wt%, the content of benzyl chloride is 1.8wt%.Due to having quaternary ammonium salt, sodium acetate and the residual of benzyl chloride, it is more difficult to determine esterification
Rate.
Comparative example 2
The preparation of heparin benzyl ester sodium salt
Benzyl chloride (100ml) is added in heparin benzyloxy b ammonium salt (100g) dichloromethane (500ml) solution.By solution
35 DEG C are heated to, is maintained 25 hours.Then add 10% sodium acetate methanol solution (600ml).Separate out precipitation, centrifugation.Will be heavy
Shallow lake is suspended in 10% sodium acetate methanol solution (600ml), is stirred 2 hours, centrifugation.Again precipitation is repeated to be suspended, centrifuged 2 times
Afterwards, precipitation is suspended in 600ml methanol, after stirring 2 hours, filtering, filter cake is rinsed with 5L methanol, is dried, is thus obtained class
White heparin benzyl ester sodium salt (32 grams).
Determined through HPLC methods, in the heparin benzyl ester sodium salt, the residual quantity of quaternary ammonium salt is 9wt%, the residual of sodium acetate
Measure as 8wt%, the residual quantity of benzyl chloride is 0.9wt%.Due to having quaternary ammonium salt, sodium acetate and the residual of benzyl chloride, it is more difficult to determine
Esterification yield.
Comparative example 3
The preparation of heparin benzyl ester sodium salt
Benzyl chloride (100ml) is added in heparin benzyloxy b ammonium salt (100g) dichloromethane (500ml) solution.By solution
35 DEG C are heated to, is maintained 25 hours.Then add 10% acetic acid sodium ethoxide solution (600ml).Separate out precipitation, centrifugation.Will be heavy
Shallow lake is suspended in 10% acetic acid sodium ethoxide solution (600ml), is stirred 2 hours, centrifugation.Again precipitation is repeated to be suspended, centrifuged 2 times
Afterwards, precipitation is suspended in 600ml ethanol, after stirring 2 hours, filtering, filter cake 5L alcohol flushings are dried, thus obtain liver
Plain benzyl ester sodium salt (30 grams).
Determined through HPLC methods, in the heparin benzyl ester sodium salt, the residual quantity of quaternary ammonium salt is 8wt%, the residual of sodium acetate
Measure as 7wt%, the residual quantity of benzyl chloride is 1.3wt%.Due to having quaternary ammonium salt, sodium acetate and the residual of benzyl chloride, it is more difficult to determine
Esterification yield.
Comparative example 4
The preparation of heparin benzyl ester sodium salt
Benzyl bromide a-bromotoluene (100ml) is added in heparin benzyloxy b ammonium salt (100g) tetrahydrofuran (500ml) solution.By solution
35 DEG C are heated to, is maintained 25 hours.Then tetrahydrofuran solvent is distilled off.Methanol is added, and can be precipitated.Illustrate liver
Plain benzyl ester benzyloxy b ammonium salt is dissolved in methanol, can not obtain heparin Bian ester sodium salt by the method for known patent.
Comparative example 5
The application of heparin benzyl ester salt
The heparin benzyl ester sodium salt (10g) that comparative example 1 is obtained is dissolved in water (250ml), obtains flaxen dirty solution, plus
Heat is to 62 DEG C.Sodium hydroxide (1g) is added into this solution, is reacted 1.5 hours, so that heparin benzyl ester sodium salt is degraded.Then will
Reactant mixture is cooled to about 20 DEG C, adds hydrochloric acid and is neutralized.Sodium chloride is added so that sodium chloride in reactant mixture
Concentration is 10% (w/v).Methanol (750ml) is added into reactant mixture, precipitation is separated out, filtering obtains filter cake, methanol washing
Afterwards, filter cake is dissolved in 100ml water.PH to 8.4 ± 0.1 is adjusted with 1M NaOH.Sodium borohydride (is pressed into 10g/kg heparin benzyl esters
Sodium salt meter) it is added in the solution, 1 hour is stood, then adjusts pH to 4.0-4.4 to eliminate excessive boron with 3M hydrochloric acid
Hydride.30 minutes are stood, and pH to 7.0 is adjusted with 2M NaOH.Sodium chloride is added, it is 10w/v%, Ran Houjia to make salinity
Enter the methanol of 3 times of volumes of liquor capacity, separate out precipitation, filtering obtains filter cake, after being washed with methanol, vacuum drying, so as to obtain
LMWHs (white, 6.2g).Calculated with liquaemin, yield is 67.0%.
After measured, the property of the polysaccharide mixture of described heparin derivative is as follows：
| Measured value | Standard | |
| Weight average molecular weight (dalton) | 4318 | 3800~5000 |
| Molecular weight is less than the constituent content of 2000 dalton | 23% | 12~20% |
| Constituent content of the molecular weight between 2000~8000 dalton | 68% | 68~82% |
| Anticoagulin xa activity (IU/ milligrams) | 93.2 | 90~125 |
| Anticoagulin IIa activity (IU/ milligrams) | 21.5 | 20~35 |
| Anticoagulin xa activity/anticoagulin IIa activity ratio | 4.3 | 3.3~5.3 |
| 1,6- dehydration ring content | 25.4% | 15~25% |
Through comparing, color is deeper than the indexs such as color requirement of the European Pharmacopoeia for Enoxaparin Sodium, and molecular weight distribution
Requirement of the European Pharmacopoeia to Enoxaparin Sodium is not met.
In addition, the content of benzethonium chloride is 0.7wt% in final products, the impurity benzylalcohol content introduced by benzyl chloride is about
0.3wt%, does not meet the requirement of injection stage Enoxaparin Sodium, hidden danger is brought to Product Safety.
Comparative example 6
The application of heparin benzyl ester salt
The heparin benzyl ester sodium salt (10g) that comparative example 2 is obtained is dissolved in water (250ml), obtains flaxen dirty solution, plus
Heat is to 63 DEG C.Sodium hydroxide (1g) is added into this solution, is reacted 1.5 hours, so that heparin benzyl ester sodium salt is degraded.Then will
Reactant mixture is cooled to about 20 DEG C, adds hydrochloric acid and is neutralized.Sodium chloride is added so that sodium chloride in reactant mixture
Concentration is 10% (w/v).Methanol (750ml) is added into reactant mixture, precipitation is separated out, filtering obtains filter cake, methanol washing
Afterwards, filter cake is dissolved in 100ml water.PH to 8.4 ± 0.1 is adjusted with 1M NaOH.Sodium borohydride (is pressed into 10g/kg heparin benzyl esters
Sodium salt meter) it is added in the solution, 1 hour is stood, then adjusts pH to 4.0-4.4 to eliminate excessive boron with 3M hydrochloric acid
Hydride.30 minutes are stood, and pH to 7.0 is adjusted with 2M NaOH.Sodium chloride is added, it is 10w/v%, Ran Houjia to make salinity
Enter the methanol of 3 times of volumes of liquor capacity, separate out precipitation, filtering obtains filter cake, after being washed with methanol, vacuum drying, so as to obtain
LMWHs (white, 7.2g).Calculated with liquaemin, yield is 69.1%.
After measured, the property of the polysaccharide mixture of described heparin derivative is as follows：
| Measured value | Standard | |
| Weight average molecular weight (dalton) | 4318 | 3800~5000 |
| Molecular weight is less than the constituent content of 2000 dalton | 25% | 12~20% |
| Constituent content of the molecular weight between 2000~8000 dalton | 69% | 68~82% |
| Anticoagulin xa activity (IU/ milligrams) | 95.1 | 90~125 |
| Anticoagulin IIa activity (IU/ milligrams) | 22.8 | 20~35 |
| Anticoagulin xa activity/anticoagulin IIa activity ratio | 4.2 | 3.3~5.3 |
| 1,6- dehydration ring content | 23.8% | 15~25% |
Through comparing, color is deeper than the indexs such as color requirement of the European Pharmacopoeia for Enoxaparin Sodium, and molecular weight distribution
Requirement of the European Pharmacopoeia to Enoxaparin Sodium is not met.
In addition, the content of benzethonium chloride is 0.6wt% in final products, the impurity benzylalcohol content introduced by benzyl chloride is about
0.3wt%, does not meet the requirement of injection stage Enoxaparin Sodium, hidden danger is brought to Product Safety.
Comparative example 7
The application of heparin benzyl ester salt
The heparin benzyl ester sodium salt (10g) that comparative example 3 is obtained is dissolved in water (250ml), obtains flaxen dirty solution, plus
Heat is to 65 DEG C.Sodium hydroxide (1.2g) is added into this solution, is reacted 1.8 hours, so that heparin benzyl ester sodium salt is degraded.Then
Reactant mixture is cooled to about 20 DEG C, hydrochloric acid is added and is neutralized.Sodium chloride is added so that chlorination in reactant mixture
Na concn is 10% (w/v).Methanol (750ml) is added into reactant mixture, precipitation is separated out, filtering obtains filter cake, and methanol is washed
After washing, filter cake is dissolved in 100ml water.PH to 8.4 ± 0.1 is adjusted with 1M NaOH.Sodium borohydride (is pressed into 10g/kg heparin benzyls
Ester sodium salt meter) it is added in the solution, 1 hour is stood, pH is then adjusted to 4.0-4.4 excessive to eliminate with 3M hydrochloric acid
Boron hydride.30 minutes are stood, and pH to 7.0 is adjusted with 2M NaOH.Sodium chloride is added, it is 10w/v% to make salinity, then
The methanol of 3 times of volumes of liquor capacity is added, precipitation is separated out, filtering obtains filter cake, after being washed with methanol, vacuum drying, so that
The LMWHs (white, 7.3g) arrived.Calculated with liquaemin, yield is 65.7%.
After measured, the property of the polysaccharide mixture of described heparin derivative is as follows：
| Measured value | Standard | |
| Weight average molecular weight (dalton) | 4412 | 3800~5000 |
| Molecular weight is less than the constituent content of 2000 dalton | 29% | 12~20% |
| Constituent content of the molecular weight between 2000~8000 dalton | 73% | 68~82% |
| Anticoagulin xa activity (IU/ milligrams) | 101.3 | 90~125 |
| Anticoagulin IIa activity (IU/ milligrams) | 23.5 | 20~35 |
| Anticoagulin xa activity/anticoagulin IIa activity ratio | 4.3 | 3.3~5.3 |
| 1,6- dehydration ring content | 23.3% | 15~25% |
Through comparing, color is deeper than color requirement of the European Pharmacopoeia for Enoxaparin Sodium, and molecular weight distribution is against regulation,
And in final products benzethonium chloride content be 0.5wt%, the impurity benzylalcohol content about 0.3wt% introduced by benzyl chloride, no
Meet the requirement of injection stage Enoxaparin Sodium, hidden danger is brought to Product Safety.
Comparative example 1~3 is compared with embodiment 2~5, even if illustrating that the amount of the increase alcohol in filtering rinses filter cake or multiple
It is suspended and is precipitated with sodium acetate methanol solution, substantial amounts of quaternary ammonium salt, benzyl chloride and acetic acid can be remained in intermediate heparin benzyl ester sodium salt
Sodium, can be to the introducing impurity of final products, while the esterification yield of more difficult accurate control heparin benzyl ester sodium salt.
Comparative example 5~7 illustrates if the quality of heparin benzyl ester sodium salt is different, particularly purity compared with embodiment 6~9
The degree of accuracy of different and esterification yield is different, then the palliating degradation degree of more difficult control heparin benzyl ester sodium salt, the LMWHs of preparation
Molecular weight distribution, color and impurity residual etc. are difficult to meet the requirements.
Embodiment 11
Pharmaceutical composition
Parenteral solution preparation (equivalent to 25mg heparin derivatives polysaccharide mixture /)
The polysaccharide mixture of heparin derivative prepared by 25g embodiments 9 is dissolved in 400ml waters for injection, is settled to
500ml.Be sterile filtered, it is filling into 1000, through quality inspection it is qualified after can apply.
All documents referred in the present invention are all incorporated as reference in this application, independent just as each document
It is incorporated as with reference to such.In addition, it is to be understood that after the above-mentioned instruction content of the present invention has been read, those skilled in the art can
To be made various changes or modifications to the present invention, these equivalent form of values equally fall within the model that the application appended claims are limited
Enclose.
Claims (34)
1. the preparation method of a kind of High-purity heparin benzyl ester alkali metal salt or alkali salt, it is characterised in that including step：
(a) by the heparin benzyl ester salt containing quaternary ammonium salt, mixed with the aqueous solution of alkali metal or alkali salt, so that instead
Heparin benzyl ester alkali metal salt or alkali salt should be generated, wherein, the heparin benzyl ester salt containing quaternary ammonium salt is following system
Standby heparin benzyl ester salt：Esterification generation heparin benzyl ester quaternary ammonium is occurred into dichloromethane for heparin quaternary ammonium salt and benzyl chloride
Salt, sodium acetate methanol solution is added into this solution, and filtering obtains heparin benzyl ester sodium salt；With
(b) in step (a) institute formation reactant mixture, add for heparin benzyl ester alkali metal salt or alkali salt
Insoluble solvent, so as to precipitate and isolate the heparin benzyl ester alkali metal salt or alkali salt；
Wherein, the solvent of described aqueous solution, is water or containing methanol, ethanol, acetone or aqueous solution of its combination, and institute
The aqueous solution concentration for stating alkali metal salt or alkali salt is 0.1w/v%~95w/v%, alkali metal salt or alkali salt
Weight ratio with the heparin benzyl ester salt containing quaternary ammonium salt is 0.1~10：1.
2. preparation method according to claim 1, it is characterised in that the alkali metal salt is sodium chloride, sodium acetate, chlorination
Potassium or sodium sulphate；The alkali salt is calcium chloride or magnesium chloride.
3. preparation method according to claim 2, it is characterised in that the alkali metal salt is sodium chloride.
4. preparation method according to claim 1, it is characterised in that the alkali metal salt or alkali salt it is aqueous molten
Liquid concentration is 3w/v%~50w/v%.
5. preparation method according to claim 1, it is characterised in that the alkali metal salt or alkali salt it is aqueous molten
Liquid concentration is 5w/v%~25w/v%.
6. preparation method according to claim 2, it is characterised in that the alkali metal salt is sodium acetate.
7. preparation method according to claim 1, it is characterised in that the alkali metal salt or alkali salt contain with described
The weight ratio for having the heparin benzyl ester salt of quaternary ammonium salt is 0.2~5：1.
8. preparation method according to claim 1, it is characterised in that the alkali metal salt or alkali salt contain with described
The weight ratio for having the heparin benzyl ester salt of quaternary ammonium salt is 0.5~1：1.
9. preparation method according to claim 1, it is characterised in that in described aqueous solution, water and organic solvent body
Product is than being 10-100：0.01-90.
10. preparation method according to claim 1, it is characterised in that described insoluble solvent is selected from the group：Alcohol, ketone,
Or its combination.
11. preparation method according to claim 10, it is characterised in that described alcohol is methanol, ethanol or its combination；
The ketone is acetone.
12. the heparin benzyl alkali metal salt or alkali salt of a kind of high-purity, it is characterised in that the content ＜ of impurity quaternary ammonium salt
5wt%, and described heparin benzyl alkali metal salt or alkali salt are prepared with any methods describeds of claim 1-11
's.
13. heparin benzyl alkali metal salt according to claim 12 or alkali salt, it is characterised in that the impurity season
The content ＜ 1wt% of ammonium salt.
14. heparin benzyl alkali metal salt according to claim 12 or alkali salt, it is characterised in that the impurity season
The content ＜ 0.5wt% of ammonium salt.
15. heparin benzyl alkali metal salt according to claim 12 or alkali salt, it is characterised in that the impurity season
The content ＜ 0.1wt% of ammonium salt.
16. heparin benzyl alkali metal salt according to claim 12 or alkali salt, it is characterised in that described heparin
Benzyl ester metal salt includes heparin benzyl ester sodium salt, sylvite, calcium salt or magnesium salts form.
17. heparin benzyl alkali metal salt according to claim 16 or alkali salt, it is characterised in that described heparin
Benzyl ester metal salt is heparin benzyl ester sodium salt.
18. a kind of method for the polysaccharide mixture for preparing heparin derivative, it is characterised in that comprise the following steps：
(a) by the heparin benzyl ester salt containing quaternary ammonium salt, mixed with the aqueous solution of alkali metal or alkali salt, so that instead
Heparin benzyl ester alkali metal salt or alkali salt should be generated, wherein, the heparin benzyl ester salt containing quaternary ammonium salt is following system
Standby heparin benzyl ester salt：Esterification generation heparin benzyl ester quaternary ammonium is occurred into dichloromethane for heparin quaternary ammonium salt and benzyl chloride
Salt, sodium acetate methanol solution is added into this solution, and filtering obtains heparin benzyl ester sodium salt；With
(b) in step (a) institute formation reactant mixture, add for heparin benzyl ester alkali metal salt or alkali salt
Insoluble solvent, so as to precipitate and isolate the heparin benzyl ester alkali metal salt or alkali salt；
(c) heparin benzyl ester alkali metal salt or alkali salt are subjected to the polysaccharide mixture that alkaline degradation obtains the heparin derivative；
Wherein, the solvent of described aqueous solution, is water or containing methanol, ethanol, acetone or aqueous solution of its combination, and institute
The aqueous solution concentration for stating alkali metal salt or alkali salt is 0.1w/v%~95w/v%, alkali metal salt or alkali salt
Weight ratio with the heparin benzyl ester salt containing quaternary ammonium salt is 0.1~10：1.
19. method according to claim 18, it is characterised in that the alkali metal salt is sodium chloride, sodium acetate, chlorination
Potassium or sodium sulphate；The alkali salt is calcium chloride or magnesium chloride.
20. method according to claim 19, it is characterised in that the alkali metal salt is sodium chloride.
21. method according to claim 18, it is characterised in that the aqueous solution of the alkali metal salt or alkali salt
Concentration is 3w/v%~50w/v%.
22. method according to claim 18, it is characterised in that the aqueous solution of the alkali metal salt or alkali salt
Concentration is 5w/v%~25w/v%.
23. method according to claim 19, it is characterised in that the alkali metal salt is sodium acetate.
24. method according to claim 18, it is characterised in that the alkali metal salt or alkali salt contain with described
The weight ratio of the heparin benzyl ester salt of quaternary ammonium salt is 0.2~5：1.
25. method according to claim 18, it is characterised in that the alkali metal salt or alkali salt contain with described
The weight ratio of the heparin benzyl ester salt of quaternary ammonium salt is 0.5~1：1.
26. method according to claim 18, it is characterised in that the solvent of described aqueous solution, is water or contains first
Alcohol, ethanol, acetone or the aqueous solution of its combination.
27. method according to claim 18, it is characterised in that described insoluble solvent is selected from the group：Alcohol, ketone or
It is combined.
28. method according to claim 27, it is characterised in that described alcohol is methanol, ethanol or its combination；It is described
Ketone is acetone.
29. a kind of polysaccharide mixture of heparin derivative, it is characterised in that with following characteristics：
Prepared by the method described in claim 18；
Weight average molecular weight is no more than 8000 dalton；
Anticoagulin Xa and anticoagulin IIa activity ratio is to be not less than 1.5；
In its non-reducing end, contain 4- pyrans uronic acid structures.
30. the polysaccharide mixture of heparin derivative according to claim 29, it is characterised in that with following characteristics：
Weight average molecular weight is 3800-5000 dalton；
Molecular weight is the 12~20% of gross weight less than the content of 2000 dalton；
Molecular weight is between the 68%-82% that the content of 2000-8000 dalton is gross weight；
Anticoagulin Xa and anticoagulin IIa activity ratio is 3.3-5.3；
In its non-reducing end, containing 4- pyrans uronic acid structures, reduction end contains 15~25% 1,6- anhydro-ring structures.
31. the polysaccharide mixture of heparin derivative according to claim 29, it is characterised in that with following characteristics：
Weight average molecular weight is 1500-5000 dalton；
Anticoagulin Xa and anticoagulin IIa activity ratio is to be not less than 10；
In its non-reducing end, contain 4- pyrans uronic acid structures.
32. the polysaccharide mixture of heparin derivative according to claim 29, it is characterised in that the polysaccharide mixture is in alkali
Metal salt or alkaline earth metal salt.
33. the polysaccharide mixture of heparin derivative according to claim 32, it is characterised in that the alkali metal salt or alkaline earth
Metallic salt form is sodium salt, sylvite, calcium salt and magnesium salts.
34. a kind of pharmaceutical composition, it is characterised in that the composition contains as described in the claim 29 of active component
The polysaccharide mixture and pharmaceutically acceptable carrier of heparin derivative.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110288821.6A CN103012621B (en) | 2011-09-26 | 2011-09-26 | A kind of High-purity heparin benzyl ester salt and its preparation method and application |
| PCT/CN2012/081981 WO2013044793A1 (en) | 2011-09-26 | 2012-09-26 | High-purity heparin benzyl ester salt, preparation method therefor and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110288821.6A CN103012621B (en) | 2011-09-26 | 2011-09-26 | A kind of High-purity heparin benzyl ester salt and its preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103012621A CN103012621A (en) | 2013-04-03 |
| CN103012621B true CN103012621B (en) | 2017-09-19 |
Family
ID=47961768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110288821.6A Active CN103012621B (en) | 2011-09-26 | 2011-09-26 | A kind of High-purity heparin benzyl ester salt and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103012621B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2003197A6 (en) * | 1987-01-05 | 1988-10-16 | Rovi Lab Farmaceut Sa | Process for the depolymerization of heparin for obtaining heparin with a low molecular weight and having an antithrombotic activity. |
| CN101711771A (en) * | 2008-10-07 | 2010-05-26 | 上海喜恩医药科技发展有限公司 | Heparin derivative polysaccharide mixture and preparation method and medicinal composition thereof |
| CN102040671A (en) * | 2009-10-13 | 2011-05-04 | 北京贯虹科技有限公司 | Process for preparing and purifying ultra low molecular weight heparin |
-
2011
- 2011-09-26 CN CN201110288821.6A patent/CN103012621B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2003197A6 (en) * | 1987-01-05 | 1988-10-16 | Rovi Lab Farmaceut Sa | Process for the depolymerization of heparin for obtaining heparin with a low molecular weight and having an antithrombotic activity. |
| CN101711771A (en) * | 2008-10-07 | 2010-05-26 | 上海喜恩医药科技发展有限公司 | Heparin derivative polysaccharide mixture and preparation method and medicinal composition thereof |
| CN102040671A (en) * | 2009-10-13 | 2011-05-04 | 北京贯虹科技有限公司 | Process for preparing and purifying ultra low molecular weight heparin |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103012621A (en) | 2013-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5389140B2 (en) | Heparin-derived polysaccharide mixture, its production and pharmaceutical composition containing it | |
| CN102558393B (en) | Preparation process of dalteparin sodium | |
| CN100467493C (en) | Producing process for low molecular weight calcium heparin | |
| CN101735336B (en) | Oligomeric fucosylated glycosaminoglycan and preparation method thereof | |
| US20110212915A1 (en) | Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them | |
| CN101711771B (en) | A kind of polysaccharide mixture of heparin derivative and method for making thereof and pharmaceutical composition | |
| WO2008028410A1 (en) | Use of low molecular weight fucoidan in the preparation of medicament for the treatment of cardiovascular and cerebrovascular diseases | |
| CN108329405A (en) | It is protected under a kind of resin adsorption state and the method for purified heparin sodium | |
| EP1261646B1 (en) | Gels of hyaluronic acid cross-linked with bi-functional l-aminoacids or l-aminoesters or mixtures thereof | |
| JP2006291028A (en) | Low-molecular heparin or salt thereof, and manufacturing method thereof | |
| CN106749748A (en) | The method that Glucose Liquid prepares polydextrose | |
| CN107033259A (en) | A kind of method of sodium acetate impurity content in reduction Enoxaparin Sodium | |
| RU2670767C1 (en) | Method for producing low molecular weight heparin | |
| CN103012621B (en) | A kind of High-purity heparin benzyl ester salt and its preparation method and application | |
| CN111217935A (en) | Micromolecule citrus pectin and preparation method thereof | |
| CN103012620B (en) | A kind of High-purity heparin benzyl ester salt and its preparation method and application | |
| CN102399306B (en) | A kind of preparation method of polysaccharide mixture of heparin derivative | |
| CN111217934B (en) | Method for removing endotoxin in pectin and pectin for removing endotoxin | |
| CN102952202A (en) | Preparation method and use of ultralow-molecular weight heparin sodium | |
| WO2014202982A1 (en) | New processes for the production of chemically-modified heparins | |
| CN104829752A (en) | Preparation method of high-purity and low-molecular-weight heparin sodium | |
| CN109666086A (en) | A kind of preparation method and applications of High-purity heparin quaternary ammonium salt | |
| CN103554305A (en) | Synthetic method of affinity precipitation medium and application thereof to preparation of enoxaparin sodium | |
| CN102399379B (en) | Polysaccharide mixture of a kind of heparin derivative and preparation method thereof and pharmaceutical composition | |
| CN107879973A (en) | A kind of process for purification of mannityl nicotinate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |